{
  "source": "PA-Notification-Nexavar.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1067-13\nProgram Prior Authorization/Notification\nMedication Nexavar® (sorafenib tosylate)\nP&T Approval Date 8/2008, 6/2009, 6/2010, 9/2010, 12/2010, 7/2011, 8/2012, 7/2013,\n8/2014, 8/2015, 8/2016, 7/2017, 7/2018, 9/2019, 9/2020, 9/2021,\n9/2022, 9/2023, 9/2024\nEffective Date 12/1/2024\n1. Background:\nNexavar® (sorafenib tosylate) is a kinase inhibitor indicated for the treatment of unresectable\nhepatocellular carcinoma, advanced renal cell carcinoma and locally recurrent or metastatic,\nprogressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.\nThe National Comprehensive Cancer Network also recommends the use of Nexavar for the\ntreatment of gastrointestinal stromal tumor (GIST), chordoma, osteosarcoma, acute myeloid\nleukemia (AML), soft tissue sarcoma, salivary gland tumors, ovarian/fallopian tube\ncancer/primary peritoneal cancer, and myeloid/lymphoid neoplasms with tyrosine kinase gene\nfusions.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Nexavar will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Renal Cell Carcinoma (RCC)\n1. Initial Authorization\na. Nexavar will be approved based on both of the following criteria:\n(1) Diagnosis of renal cell carcinoma (RCC)\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) One of the following:\n(a) Disease has relapsed\n-OR-\n(b) Both of the followi",
    "th of the following criteria:\n(1) Diagnosis of renal cell carcinoma (RCC)\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) One of the following:\n(a) Disease has relapsed\n-OR-\n(b) Both of the following:\ni. Medically or surgically unresectable tumor\nii. Diagnosis of Stage IV disease\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nexavar will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Nexavar\ntherapy\nAuthorization will be issued for 12 months.\nC. Hepatocellular Carcinoma\n1. Initial Authorization\na. Nexavar will be approved based on both of the following criteria:\n(1) Diagnosis of hepatocellular carcinoma\n-AND-\n(2) One of the following:\n(a) Patient has metastatic disease\n-OR-\n(b) Patient has extensive liver tumor burden\n-OR-\n(c) Patient is inoperable by performance status or comorbidity (local\ndisease or local disease with minimal extrahepatic disease only)\n-OR-\n(d) Both of the following:\n© 2024 UnitedHealthcare Services, Inc.\n2\ni. Patient is not a transplant candidate\nii. Disease is unresectable\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nexavar will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Nexavar\ntherapy\nAuthorization will be issued for 12 months.\nD. Thyroid Cancer\n1. Initial Authorization\na. Nexavar will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Diagnosis of one of the following:\ni. Follicular carcinoma\nii. Oncocytic carcinoma\niii. Papillary carcinoma\n-AND-\n(b) One of the following:\ni. Unresectable recurrent disease\nii. Persistent locoregional disease\niii. Metastatic disease\n-AND-\n(c) One of the following:\ni. Patient has symptomatic disease\nii. Patient has progressive disease\n-AND-\n(d) Disease is refractory to radioactive iodine treatment\n-OR-\n© 2024 UnitedHealthcare Services, Inc.\n3\n(2) All of the following:\n(a) Diagnosis of medullary thyroid ",
    "ient has progressive disease\n-AND-\n(d) Disease is refractory to radioactive iodine treatment\n-OR-\n© 2024 UnitedHealthcare Services, Inc.\n3\n(2) All of the following:\n(a) Diagnosis of medullary thyroid carcinoma\n-AND-\n(b) One of the following:\ni. Disease is progressive\nii. Disease is symptomatic with distant metastases\n-AND-\n(c) History of failure, contraindication, or intolerance to one of the\nfollowing:\ni. Caprelsa (vandetanib)\nii. Cometriq (cabozantinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nexavar will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Nexavar\ntherapy\nAuthorization will be issued for 12 months.\nE. Soft Tissue Sarcoma\n1. Initial Authorization\na. Nexavar will be approved based on one of the following criteria:\n(1) Diagnosis of angiosarcoma\n-OR-\n(2) Diagnosis of desmoid tumors / aggressive fibromatosis\n-OR-\n(3) Both of the following:\n(a) Diagnosis of progressive gastrointestinal stromal tumors (GIST)\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n4\n(b) History of failure, contraindication, or intolerance to one of the following:\ni. Gleevec (imatinib)\nii. Sutent (sunitinib)\niii. Stivarga (regorafenig)\niv. Qinlock (ripretinib)\n-OR-\n(4) Diagnosis of solitary fibrous tumor/hemangiopericytoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nexavar will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Nexavar\ntherapy\nAuthorization will be issued for 12 months.\nF. Bone Cancer\n1. Initial Authorization\na. Nexavar will be approved based on the following criteria:\n(1) Both of the following:\n(a) Diagnosis of chordoma\n-AND-\n(b) Disease is recurrent\n-OR-\n(2) Both of the following\n(a) One of the following:\ni. Diagnosis of osteosarcoma\nii. Diagnosis of dedifferentiated chondrosarcoma\nii. Diagnosis of high-grade undifferentiated pleomorphic sarcoma (UPS)\n-AND-\n(b) Not used as first-line therapy\n© 20",
    "wing:\ni. Diagnosis of osteosarcoma\nii. Diagnosis of dedifferentiated chondrosarcoma\nii. Diagnosis of high-grade undifferentiated pleomorphic sarcoma (UPS)\n-AND-\n(b) Not used as first-line therapy\n© 2024 UnitedHealthcare Services, Inc.\n5\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nexavar will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Nexavar\ntherapy\nAuthorization will be issued for 12 months.\nG. Acute Myeloid Leukemia\n1. Initial Authorization\na. Nexavar will be approved based on all of the following criteria:\n(1) Diagnosis of acute myeloid leukemia (AML)\n-AND-\n(2) Patient has FLT3-ITD mutation-positive disease\n-AND-\n(3) One of the following:\n(a) Patient has relapsed disease\n(b) Patient has refractory disease\n-AND-\n(4) Used in combination with one of the following:\n(a) Vidaza (azacitidine)\n(b) Dacogen (decitabine)\n-AND-\n(5) Patient is unable to tolerate more aggressive treatment regimens\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nexavar will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Nexavar\ntherapy\n© 2024 UnitedHealthcare Services, Inc.\n6\nAuthorization will be issued for 12 months.\nH. Ovarian Cancer\n1. Initial Authorization\na. Nexavar will be approved based on all of the following criteria:\n(1) Diagnosis of one of the following:\n(a) Ovarian cancer\n(b) Fallopian tube cancer\n(c) Primary peritoneal cancer\n-AND-\n(2) One of the following:\n(a) Patient has persistent disease\n(b) Patient has recurrent disease\n-AND-\n(3) Disease is platinum-resistant\n-AND-\n(4) Used in combination with topotecan\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nexavar will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Nexavar\ntherapy\nAuthorization will be issued for 12 months.\nI. Salivary Gland Tumor\n1. Initial Authorization\na.",
    " following criterion:\n(1) Patient does not show evidence of progressive disease while on Nexavar\ntherapy\nAuthorization will be issued for 12 months.\nI. Salivary Gland Tumor\n1. Initial Authorization\na. Nexavar will be approved based on all of the following criteria:\n(1) Diagnosis of salivary gland tumor\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n7\n(2) Disease is one of the following:\n(a) Recurrent and unresectable\n(b) Metastatic\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nexavar will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Nexavar\ntherapy\nAuthorization will be issued for 12 months.\nJ. Myeloid/Lymphoid Neoplasms\n1. Initial Authorization\na. Nexavar will be approved based on all of the following criteria:\n(1) Diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FLT3\nrearrangement\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nexavar will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Nexavar\ntherapy\nAuthorization will be issued for 12 months.\nK. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n8\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n• Suppl",
    "\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n• Supply limit may be in place.\n4. References:\n1. Nexavar [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; August 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org . Accessed July 28, 2024.\nProgram Prior Authorization/Notification - Nexavar (sorafenib tosylate)\nChange Control\n8/2014 Annual review with changes to Coverage Criteria for hepatocellular\ncarcinoma, GIST and Thyroid Cancer. Updated formatting, Background\nand References.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n8/2015 Annual review. Updated thyroid cancer and osteosarcoma criteria.\nMoved GIST criteria under soft tissue sarcoma. Added AML criteria.\nIncreased authorization and reauthorization from 6 months to 12\nmonths for all indications. Updated background and references.\n7/2016 Annual review. Revised criteria for renal cell cancer. Updated\nreferences.\n7/2017 Annual review. Updated background and criteria for the following\nbone cancers; chordoma, dedifferentiated chondorosarcoma, and high-\ngrade undifferentiated pleomorphic sarcoma (UPS) per NCCN\nguidelines. Updated references.\n7/2018 Annual review. Updated background and added criteria for solitary\nfibrous tumor/hemangiopericytoma. Updated references.\n9/2019 Annual review. Updated background and added criteria for platinum-\nresistant ovarian cancer. Updated references. Added general NCCN\nrecommended review criteria.\n9/2020 Annual review with no changes to clinical coverage criteria. Updated\nreferences.\n9/2021 Annual review with no changes to coverage criteria. Updated\nreferences.\n9/2022 Annual review. Added criteria for salivary gland tumors and\nmyeloid/lymphoid neoplasms. Added state mandate disclaimer and\nupdated references.\n9/2023 Replaced Hürthle cell wit",
    "dated\nreferences.\n9/2022 Annual review. Added criteria for salivary gland tumors and\nmyeloid/lymphoid neoplasms. Added state mandate disclaimer and\nupdated references.\n9/2023 Replaced Hürthle cell with Oncocytic within Thyroid Cancer coverage\ncriteria. Added Qinlock to NCCN recommended first-line therapies for\n© 2024 UnitedHealthcare Services, Inc.\n9\nGIST. Updated background and references.\n9/2024 Annual review with no changes. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n10"
  ]
}